公开(公告)号：US11884713B2

公开(公告)日：2024-01-30

申请号：US17369061

申请日：2021-07-07

申请人： Zealand Pharma A/S

发明人： Ditte Riber ,  Jakob Lind Tolborg ,  Dieter Wolfgang Hamprecht ,  Wolfgang Rist

IPC分类号： C07K14/605 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61K31/137 ,  A61K31/155 ,  A61K31/198 ,  A61K31/485 ,  A61K31/7048

CPC分类号： C07K14/605 ,  A61K31/137 ,  A61K31/155 ,  A61K31/198 ,  A61K31/485 ,  A61K31/7048 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61K38/26 ,  A61K2300/00 ,  A61K38/28 ,  A61K2300/00 ,  A61K31/155 ,  A61K2300/00 ,  A61K31/198 ,  A61K2300/00 ,  A61K31/137 ,  A61K2300/00 ,  A61K31/7048 ,  A61K2300/00 ,  A61K31/485 ,  A61K2300/00

摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

公开(公告)号：US11034747B2

公开(公告)日：2021-06-15

申请号：US15971645

申请日：2018-05-04

申请人： Zealand Pharma A/S

发明人： Ditte Riber ,  Jakob Lind Tolborg ,  Dieter Wolfgang Hamprecht

IPC分类号： C07K14/605 ,  A61K38/00

摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

公开(公告)号：US09975939B2

公开(公告)日：2018-05-22

申请号：US14864256

申请日：2015-09-24

申请人： Zealand Pharma A/S

发明人： Jakob Lind Tolborg ,  Keld Fosgerau ,  Pia Nørregaard ,  Rasmus Just ,  Ditte Riber ,  Dieter Wolfgang Hamprecht ,  Robert Augustin ,  Leo Thomas ,  Wolfgang Rist

IPC分类号： A61K38/00 ,  C07K14/605 ,  A61K38/26 ,  A61K45/06

CPC分类号： C07K14/605 ,  A61K38/26 ,  A61K45/06

摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

公开(公告)号：US09657062B2

公开(公告)日：2017-05-23

申请号：US14376088

申请日：2013-02-01

申请人： Zealand Pharma A/S

发明人： Simon Birksø Larsen ,  Ditte Riber

IPC分类号： A61K38/25 ,  C07K14/60 ,  C07K14/00 ,  A61K38/00

CPC分类号： C07K14/001 ,  A61K38/00 ,  C07K14/60

摘要： The present invention relates, inter alia, to ghrelin analogs and their medical use, for example in the treatment of cachexia, chronic obstructive pulmonary disease, gastrointestinal disorders (e.g., gastroparesis and/or inflammatory disorders such as colitis, gut barrier dysfunction, and ischemia reperfusion injury), loss of body weight, and decreased appetite.

公开(公告)号：US20150210744A1

公开(公告)日：2015-07-30

申请号：US14417074

申请日：2013-07-23

申请人： Zealand Pharma A/S

发明人： Ditte Riber ,  Lise Giehm

IPC分类号： C07K14/605

CPC分类号： C07K14/605 ,  A61K38/00 ,  A61K38/26

摘要： The present invention relates to glucagon analogues and their medical use, for example in the treatment of hypoglycaemia. In particular, the present invention relates to stable glucagon analogues suitable for use in a liquid formulation.

摘要翻译： 本发明涉及胰高血糖素类似物及其医学用途，例如用于治疗低血糖。 特别地，本发明涉及适用于液体制剂的稳定的胰高血糖素类似物。

公开(公告)号：US20150125431A1

公开(公告)日：2015-05-07

申请号：US14398297

申请日：2013-05-03

申请人： Zealand Pharma A/S

发明人： Rasmus Just ,  Kirsten Lindegaard Bovbjerg ,  Ditte Riber ,  Wayne Shaun Russell

IPC分类号： C07K14/605 ,  A61K35/54 ,  A61K35/64 ,  A61K35/22 ,  A61K35/48 ,  A61K38/26 ,  A61K45/06

CPC分类号： C07K14/605 ,  A61K35/22 ,  A61K35/48 ,  A61K35/54 ,  A61K35/63 ,  A61K35/64 ,  A61K38/26 ,  A61K45/06

摘要： GLP-2 analogues are disclosed which comprise one of more substitutions as compared to h[Gly2]GLP-2 and which may have the property of an altered GLP-1 activity, and their medical use. The analogues are particularly useful for the prophylaxis, treatment or ameliorating of the gastro-intestinal associated side effects of diabetes.

摘要翻译： 公开了GLP-2类似物，其包含与h [Gly2] GLP-2相比更多的取代，并且其可具有改变的GLP-1活性的性质及其医疗用途。 类似物对于预防，治疗或改善糖尿病的胃肠相关副作用特别有用。

公开(公告)号：US20140127174A1

公开(公告)日：2014-05-08

申请号：US14149640

申请日：2014-01-07

申请人： Zealand Pharma A/S

发明人： Eddi MEIER ,  Ditte Riber ,  Marie Skovgaard ,  Bjarne D. Larsen ,  Jens R. Daugaard ,  Trine S. R. Neerup

IPC分类号： C07K14/605

CPC分类号： C07K14/605 ,  A61K38/00

摘要： The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

摘要翻译： 本发明提供用于促进体重减轻或预防体重增加以及治疗糖尿病，代谢综合征和相关疾病的材料和方法。 特别地，本发明提供了在这些方法中有效的新型胰高血糖素类似物肽。 与人胰高血糖素相比，肽可以通过增加对GLP-1受体的选择性而介导其作用。

公开(公告)号：US10336802B2

公开(公告)日：2019-07-02

申请号：US15566338

申请日：2016-04-15

申请人： Zealand Pharma A/S ,  Boehringer Ingelheim International GmbH

发明人： Ditte Riber ,  Jakob Lind Tolborg ,  Dieter Wolfgang Hamprecht ,  Leo Thomas

IPC分类号： A61K31/64 ,  A61K38/22 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61K31/135 ,  A61K31/137 ,  A61K31/155 ,  A61K31/365 ,  C07K14/605 ,  A61K31/7048

摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

公开(公告)号：US10253081B2

公开(公告)日：2019-04-09

申请号：US15983822

申请日：2018-05-18

申请人： Zealand Pharma A/S

发明人： Jakob Lind Tolborg ,  Keld Fosgerau ,  Pia Nørregaard ,  Rasmus Just ,  Ditte Riber ,  Dieter Wolfgang Hamprecht ,  Robert Augustin ,  Leo Thomas ,  Wolfgang Rist

IPC分类号： A61K38/00 ,  C07K14/605 ,  A61K38/26 ,  A61K45/06

摘要： The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

公开(公告)号：US10004786B2

公开(公告)日：2018-06-26

申请号：US14843047

申请日：2015-09-02

申请人： Zealand Pharma A/S

发明人： Ditte Riber ,  Eddi Meier ,  Jens Rosengren Daugaard ,  Marie Skovgaard ,  Jakob Lind Tolborg ,  Gita Kampen ,  Camilla Ærteberg Bæk

IPC分类号： A61K38/00 ,  A61K38/26 ,  C07K14/605 ,  A61K47/48

CPC分类号： A61K38/26 ,  A61K47/54 ,  C07K14/605

摘要： The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.